Log in

Becton, Dickinson and Stock Forecast, Price & News

+1.49 (+0.66 %)
(As of 11/27/2020 12:00 AM ET)
Today's Range
Now: $228.96
50-Day Range
MA: $236.57
52-Week Range
Now: $228.96
Volume849,119 shs
Average Volume1.86 million shs
Market Capitalization$66.37 billion
P/E Ratio83.87
Dividend Yield1.39%
Becton, Dickinson and Company develops, manufactures, and sells medical supplies, devices, laboratory equipment, and diagnostic products worldwide. The company's BD Medical segment offers peripheral IV and advanced peripheral catheters, central lines, acute dialysis catheters, vascular care and preparation products, needle-free IV connectors and extensions sets, IV fluids, closed-system drug transfer devices, hazardous drug detection, hypodermic syringes and needles, anesthesia needles and trays, enteral syringes, sharps disposal systems; infusion pumps and dedicated disposables, medication compounding workflow systems, automated medication dispensing, automated supply management systems, medication inventory optimization and tracking systems; syringes, pen needles, and other products for diabetes care; and prefillable drug delivery systems. Its BD Life Sciences segment provides specimen and blood collection products and systems; automated blood and tuberculosis culturing, molecular testing, microorganism identification and drug susceptibility, and liquid-based cytology systems, as well as rapid diagnostic assays, microbiology laboratory automation products, and plated media products; and fluorescence-activated cell sorters and analyzers, antibodies and kits, reagent systems, and solutions for high-throughput single-cell gene expression analysis, as well as clinical oncology, immunological, and transplantation diagnostic/monitoring reagents and analyzers. The company's BD Interventional segment offers hernia and soft tissue repair, biological and bioresorbable grafts, biosurgery, and other surgical products; surgical infection prevention, surgical and laparoscopic instrumentation products; peripheral intervention products; and urology and critical care products. It has a strategic partnership with the Biomedical Advanced Research and Development Authority to develop new manufacturing lines for injection devices. Becton, Dickinson and Company was founded in 1897 and is based in Franklin Lakes, New Jersey.
Read More
Becton, Dickinson and logo

Beat the Market (BTM) Rank

Analyst Opinion: 2.3Community Rank: 2.3Dividend Strength: 3.3Insider Behavior: 1.7Valuation: 0.6 5 -4 -3 -2 -1 -

Overall Beat the Market Rank

2.05 out of 5 stars

Industry, Sector and Symbol

Industry Surgical & medical instruments
Sub-IndustryHealth Care Equipment



Sales & Book Value

Annual Sales$17.12 billion
Cash Flow$17.72 per share
Book Value$82.02 per share


Net Income$874 million


Market Cap$66.37 billion
Next Earnings Date2/4/2021 (Estimated)
+1.49 (+0.66 %)
(As of 11/27/2020 12:00 AM ET)
30 days | 90 days | 365 days | Advanced Chart

Receive BDX News and Ratings via Email

Sign-up to receive the latest news and ratings for BDX and its competitors with MarketBeat's FREE daily newsletter.

speech bubbles
speech bubbles

Becton, Dickinson and (NYSE:BDX) Frequently Asked Questions

How has Becton, Dickinson and's stock price been impacted by Coronavirus?

Becton, Dickinson and's stock was trading at $231.91 on March 11th, 2020 when Coronavirus reached pandemic status according to the World Health Organization. Since then, BDX shares have decreased by 1.3% and is now trading at $228.96.
View which stocks have been most impacted by COVID-19

Do Wall Street analysts recommend investors buy shares of Becton, Dickinson and?

15 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Becton, Dickinson and in the last year. There are currently 7 hold ratings, 7 buy ratings and 1 strong buy rating for the stock, resulting in a consensus recommendation of "Buy."
View analyst ratings for Becton, Dickinson and

What stocks does MarketBeat like better than Becton, Dickinson and?

Wall Street analysts have given Becton, Dickinson and a "Buy" rating, but there may be better short-term opportunities in the market. Some of MarketBeat's winning trading ideas this year have resulted in 5-15% weekly gains. MarketBeat just released five new trading ideas, but Becton, Dickinson and wasn't one of them. MarketBeat thinks these five stocks may be even better buys.
View MarketBeat's top stock picks here.

When is Becton, Dickinson and's next earnings date?

Becton, Dickinson and is scheduled to release its next quarterly earnings announcement on Thursday, February 4th 2021.
View our earnings forecast for Becton, Dickinson and

How were Becton, Dickinson and's earnings last quarter?

Becton, Dickinson and Company (NYSE:BDX) announced its quarterly earnings data on Tuesday, November, 10th. The medical instruments supplier reported $2.79 earnings per share (EPS) for the quarter, beating the consensus estimate of $2.52 by $0.27. The medical instruments supplier had revenue of $4.78 billion for the quarter, compared to the consensus estimate of $4.48 billion. Becton, Dickinson and had a return on equity of 13.30% and a net margin of 5.11%. The business's quarterly revenue was up 4.4% compared to the same quarter last year. During the same period in the prior year, the business posted $3.31 EPS.
View Becton, Dickinson and's earnings history

How often does Becton, Dickinson and pay dividends? What is the dividend yield for Becton, Dickinson and?

Becton, Dickinson and announced a quarterly dividend on Tuesday, November 24th. Investors of record on Thursday, December 10th will be paid a dividend of $0.83 per share on Thursday, December 31st. This represents a $3.32 dividend on an annualized basis and a yield of 1.45%. The ex-dividend date is Wednesday, December 9th. This is a boost from Becton, Dickinson and's previous quarterly dividend of $0.79.
View Becton, Dickinson and's dividend history

What guidance has Becton, Dickinson and issued on next quarter's earnings?

Becton, Dickinson and issued an update on its FY21 earnings guidance on Thursday, November, 5th. The company provided EPS guidance of $12.40-12.60 for the period, compared to the Thomson Reuters consensus estimate of $12.53. The company issued revenue guidance of ~$18.49-$19.17 billion, compared to the consensus revenue estimate of $18.78 billion.

What price target have analysts set for BDX?

15 equities research analysts have issued twelve-month price targets for Becton, Dickinson and's shares. Their forecasts range from $260.00 to $300.00. On average, they expect Becton, Dickinson and's share price to reach $280.29 in the next twelve months. This suggests a possible upside of 22.4% from the stock's current price.
View analysts' price targets for Becton, Dickinson and

Are investors shorting Becton, Dickinson and?

Becton, Dickinson and saw a increase in short interest in October. As of October 30th, there was short interest totaling 2,170,000 shares, an increase of 15.4% from the October 15th total of 1,880,000 shares. Based on an average trading volume of 1,430,000 shares, the short-interest ratio is presently 1.5 days.
View Becton, Dickinson and's Short Interest

Who are some of Becton, Dickinson and's key competitors?

What other stocks do shareholders of Becton, Dickinson and own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Becton, Dickinson and investors own include Johnson & Johnson (JNJ), AbbVie (ABBV), AT&T (T), NVIDIA (NVDA), The Walt Disney (DIS), Abbott Laboratories (ABT), Intel (INTC), Verizon Communications (VZ), Cisco Systems (CSCO) and CVS Health (CVS).

Who are Becton, Dickinson and's key executives?

Becton, Dickinson and's management team includes the following people:
  • Mr. Vincent A. Forlenza, Exec. Chairman (Age 67, Pay $3.26M)
  • Mr. Thomas E. Polen Jr., Pres, CEO & Director (Age 47, Pay $1.93M)
  • Mr. Christopher R. Reidy, Exec. VP, CFO & Chief Admin. Officer (Age 63, Pay $1.74M)
  • Mr. Alberto Mas, Exec. VP & Pres of the Medical Segment (Age 59, Pay $1.32M)
  • Mr. Patrick K. Kaltenbach, Exec. VP & Pres of the Life Sciences Segment (Age 57, Pay $2.03M)
  • Mr. Thomas J. Spoerel, VP, Controller & Chief Accounting Officer (Age 42)
  • Mr. Charles R. Bodner, Sr. VP of Corp. Fin. (Age 49)
  • Dr. John A. DeFord, Exec. VP of R&D and CTO (Age 58)
  • Jerry Flasz, Exec. VP of Global Services & Chief Information Officer
  • Ms. Monique N. Dolecki, Sr. VP of Investor Relations

What is Becton, Dickinson and's stock symbol?

Becton, Dickinson and trades on the New York Stock Exchange (NYSE) under the ticker symbol "BDX."

Who are Becton, Dickinson and's major shareholders?

Becton, Dickinson and's stock is owned by many different retail and institutional investors. Top institutional investors include BlackRock Inc. (7.38%), State Street Corp (4.26%), Morgan Stanley (2.62%), Massachusetts Financial Services Co. MA (1.57%), Wells Fargo & Company MN (1.26%) and JPMorgan Chase & Co. (1.21%). Company insiders that own Becton, Dickinson and stock include Alexandre Conroy, Betty D Larson, Catherine M Burzik, Charles R Bodner, Claire Fraser, James C Lim, James W Borzi, Patrick Kaltenbach, Ribo Alberto Mas, Roland Goette, Samrat S Khichi, Simon D Campion, Thomas J Spoerel and Vincent A Forlenza.
View institutional ownership trends for Becton, Dickinson and

Which institutional investors are selling Becton, Dickinson and stock?

BDX stock was sold by a variety of institutional investors in the last quarter, including Findlay Park Partners LLP, CI Investments Inc., Charles Schwab Investment Management Inc., Montag & Caldwell LLC, Cibc World Markets Corp, Neuberger Berman Group LLC, TD Asset Management Inc., and KBC Group NV. Company insiders that have sold Becton, Dickinson and company stock in the last year include Claire Fraser, Patrick Kaltenbach, Ribo Alberto Mas, Roland Goette, Simon D Campion, Thomas J Spoerel, and Vincent A Forlenza.
View insider buying and selling activity for Becton, Dickinson and

Which institutional investors are buying Becton, Dickinson and stock?

BDX stock was purchased by a variety of institutional investors in the last quarter, including BlackRock Inc., Morgan Stanley, The Manufacturers Life Insurance Company, Massachusetts Financial Services Co. MA, CIBC Private Wealth Group LLC, State of Tennessee Treasury Department, AustralianSuper Pty Ltd, and JPMorgan Chase & Co..
View insider buying and selling activity for Becton, Dickinson and

How do I buy shares of Becton, Dickinson and?

Shares of BDX can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.

What is Becton, Dickinson and's stock price today?

One share of BDX stock can currently be purchased for approximately $228.96.

How big of a company is Becton, Dickinson and?

Becton, Dickinson and has a market capitalization of $66.37 billion and generates $17.12 billion in revenue each year. The medical instruments supplier earns $874 million in net income (profit) each year or $10.20 on an earnings per share basis. Becton, Dickinson and employs 70,093 workers across the globe.

What is Becton, Dickinson and's official website?

The official website for Becton, Dickinson and is www.bd.com.

How can I contact Becton, Dickinson and?

Becton, Dickinson and's mailing address is 1 BECTON DRIVE, FRANKLIN LAKES NJ, 07417. The medical instruments supplier can be reached via phone at 201-847-6800.

This page was last updated on 11/28/2020 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.